Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Buy" by Analysts

Shares of Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) have been given an average recommendation of "Buy" by the eight research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $14.67.

Several equities research analysts recently issued reports on NKTX shares. Stifel Nicolaus decreased their price target on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 27th. Needham & Company LLC dropped their price target on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. William Blair reissued a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. Finally, HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th.

Nkarta Stock Down 5.6%

Shares of NKTX traded down $0.10 during trading hours on Friday, hitting $1.70. 351,961 shares of the company were exchanged, compared to its average volume of 1,066,344. The company has a market cap of $120.63 million, a price-to-earnings ratio of -0.90 and a beta of 0.81. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $8.23. The firm's fifty day moving average is $1.79 and its 200 day moving average is $2.17.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01. Analysts anticipate that Nkarta will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Nkarta

A number of institutional investors have recently added to or reduced their stakes in NKTX. Jefferies Financial Group Inc. increased its stake in Nkarta by 901.7% in the 4th quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company's stock worth $6,236,000 after acquiring an additional 2,254,219 shares during the last quarter. Tang Capital Management LLC increased its position in shares of Nkarta by 252.9% during the 4th quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company's stock valued at $5,711,000 after purchasing an additional 1,643,719 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock valued at $6,319,000 after purchasing an additional 1,474,560 shares during the last quarter. Jane Street Group LLC increased its position in shares of Nkarta by 118.7% during the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock valued at $247,000 after purchasing an additional 852,559 shares during the last quarter. Finally, Monaco Asset Management SAM bought a new position in shares of Nkarta during the 1st quarter valued at about $1,496,000. 80.54% of the stock is currently owned by institutional investors.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.